Grace Therapeutics Q3 EPS $(0.14) Beats $(0.28) Estimate

Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.28) by 50 percent. This is a 61.11 percent increase over losses of $(0.36) per share from the same period last year.